Skip to content
cccskills
FreePublished on GitHub

jes-pa-dexamethasone-test

Identifies patients with adrenal tumors on CT who should undergo dexamethasone suppression test to evaluate for autonomous cortisol co-secretion. Triggers include when a clinician finds an adrenal tumor on CT and asks 'Should I test for cortisol co-secretion?' or is planning AVS for a tumor >3.0 cm.

The English summary is being prepared. Showing the original description.

See how to install

Files included (1)

  • SKILL.md2.4 KB

SKILL.md (original)

Review the instructions the agent will receive before you install.

Determine when to perform dexamethasone suppression test for cortisol co-secretion

STEP 1 — Gather Information

Document adrenal tumor presence on CT (size, laterality) and assess for hypertension or hypokalemia.
Action: Record tumor size and proceed to size‑based decision.

STEP 2 — Rule In / Rule Out

Is an adrenal tumor identified on CT?

  • Yes: Proceed to Step 3.
  • No: Dexamethasone suppression test not indicated for cortisol co‑secretion evaluation.

STEP 3 — Classify or Stratify

Stratify by tumor size: >3.0 cm vs ≤3.0 cm.
Action: If tumor >3.0 cm, proceed to dexamethasone suppression test; if ≤3.0 cm, consider test based on additional clinical features (e.g., hypertension, hypokalemia).

STEP 4 — Decide

Administer 1 mg dexamethasone at night; measure serum cortisol the next morning between 8–9 am.

  • Cortisol ≥1.8 μg/dL: Diagnose autonomous cortisol co‑secretion.
  • Cortisol <1.8 μg/dL: No autonomous cortisol co‑secretion detected.

Clinical Guardrails / Mimics / Pitfalls

Do not test in patients receiving exogenous glucocorticoids; ensure proper dexamethasone dosing and timing; avoid false positives from acute stress or illness; test evaluates subclinical cortisol excess, not frank Cushing’s syndrome; interpret results in clinical context and coordinate peri‑operative stress‑dose glucocorticoids if surgery planned.

Concrete Clinical Example

A 60‑year‑old woman with hypertension and mild hypokalemia has an incidentally discovered 3.5 cm left adrenal nodule on CT; the clinician planning AVS asks about cortisol co‑secretion. A 1 mg overnight dexamethasone suppression test yields a morning cortisol of 2.4 μg/dL (≥1.8 μg/dL), indicating autonomous cortisol co‑secretion. She is referred for adrenalectomy with peri‑operative stress‑dose glucocorticoid coverage.

Source: Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021, Japan Endocrine Society, 2021

Reviews

No reviews yet. Tell others what you thought.

Comments

No login needed. Share how it worked for you, ask a question, or note where it did not run.

No comments yet. Be the first to write one.

Comments are published right away. Do not include personal information such as email addresses or phone numbers. Up to 2 URLs.

0 / 1,000 characters

This form is protected by reCAPTCHA, and the Google Privacy Policy and Terms of Service apply.

More skills from this repository

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

The English summary is being prepared. Showing the original description.

dromlakhani/MD2SKILL14Updated Oct 20, 2026

See all skills by dromlakhani

Report a problem with this skill